作为第二代组胺H1受体对手的阿斯泰米,并没有减轻α-Synuclein在体外的聚合过程
Jung Il Choi1, Hyunjo Lee2, Dong Jun Kim1
1Basic-Clinical Convergence Research Institute, University of Ulsan, Ulsan 44033, Republic of Korea.
Biomedicines
|March 28, 2024
概括
在帕金森病模型中,抗胺抗菌素astemizole不会抑制α-synuclein聚合. 在临床前研究中,它的有益作用可能来自其他机制,而不是α-synuclein调节.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 在临床前帕金森病 (PD) 模型中,抗胰岛素astemizole显示出有希望的结果.
- 阿斯泰米也会影响粉样β (Aβ) 聚合和蛋白 (PrPSc).
- 阿斯泰米的PD益处的机制尚不清楚,可能涉及α-synuclein (α-syn) 聚合.
研究的目的:
- 为了调查astemizole是否抑制病理性α-synuclein (α-syn) 聚合.
- 为了确定astemizole对粉样蛋白的作用是否具有标选择性.
主要方法:
- 提奥夫拉T聚合的监测.
- 刚果红色的光谱分析.
- 细胞活力测试. 细胞活力测试.
- 传输电子显微镜 (TEM). 传输电子显微镜.
主要成果:
- 在体外,即使在高度下,阿斯泰米也不能抑制α-syn聚合.
- 阿斯泰米醇对粉样β (Aβ) 聚合物的组合有抑制作用.
- 研究结果表明,astemizole的抗粉样蛋白活性是特定于蛋白质的.
结论:
- 在帕金森病模型中,Astemizole的建议益处不太可能通过直接抑制α-syn聚合来调解.
- 阿斯泰米的治疗效果可能涉及其他分子点或途径.
- 阿斯泰米醇表现出粉样蛋白组合的向选择性抑制.
相关概念视频
Drugs Affecting Neurotransmitter Release or Uptake
1.8K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.8K
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Upper Respiratory Drugs: First and Second-Generation Antihistamines
1.8K
Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
1.8K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
1.3K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.3K


